SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.58+0.9%Dec 10 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (8368)5/15/2003 1:06:57 PM
From: Biomaven  Read Replies (2) of 52153
 
Thanks, Erik - I didn't know that. So maybe the FDA will be reasonable going forward.

The FDA's original distaste for combination drugs comes from them seeing this as an attempt to extend patent life and they also saw it as taking away dosing flexibility. But of course they sometimes do approve them - KOSP's Advicor is an example, and in antibiotics there is the commonly used Bactrim (Trimethoprim-Sulfamethoxazole combo).

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News